Dong-A Eyes Expanded Evogliptin Markets Via Tobira NASH Deal
This article was originally published in PharmAsia News
Executive Summary
Dong-A ST’s in-house developed DPP-4 inhibitor evogliptin is set to enter major markets, including the US and Europe, through a new licensing deal with Tobira that will focus on the treatment of non-alcoholic steatohepatitis (NASH) rather than diabetes.
You may also be interested in...
Pursuing Productive Pharma Partnerships In Korea
Multinational and domestic pharma companies operating in South Korea should develop partnerships that build on each others’ strengths, delegates at a recent conference in Seoul heard.
AbbVie Picks Up Dong-A Candidate As It Makes Immuno-Onc Inroads
Dong-A ST has scored a major early success in its inroads into cancer R&D through a sizable immuno-oncology deal with AbbVie, which also underscores the US firm’s push to expand its assets in the area.
Tobira, Dong-A Stick To NASH Plans Despite CENTAUR Results
The failure of Tobira's cenicriviroc to meet its primary endpoint in the CENTAUR study has raised some concerns in South Korea over the prospects for a combo therapy with Dong-A ST's evogliptin. But the two firms are sticking to their clinical development plans based on the positive secondary endpoint outcome in the study.